Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma

NCT02661282 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

65

Enrollment

OTHER

Sponsor class

Conditions

Cytomegalovirus Positive
Glioblastoma
Gliosarcoma
Malignant Glioma
Recurrent Brain Neoplasm
Recurrent Glioblastoma

Interventions

BIOLOGICAL: Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes
OTHER: Laboratory Biomarker Analysis
DRUG: Temozolomide
PROCEDURE: Therapeutic Conventional Surgery

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]